Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748980 | 0.97 | MET (0.51) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2748772 | 0.92 | MET (0.51) | METTTKTNK2FLT3 | |
| SCHEMBL2749393 | 0.92 | MET (0.51) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2749132 | 0.89 | MET (0.53) | METTTKTNK2 | |
| SCHEMBL2749793 | 0.89 | MET (0.49) | METTTKTNK2 | |
| SCHEMBL2749172 | 0.89 | MET (0.49) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2749402 | 0.88 | MET (0.51) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2749485 | 0.88 | MET (0.52) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2749567 | 0.86 | TNK2 (0.53) | METTTKTNK2FGFR1FGFR2 | |
| SCHEMBL2747982 | 0.86 | MET (0.49) | METTTKTNK2FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | MET 38/4885TTK 774/4885TNK2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.